Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 3, 2026
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateGlobeNewsWire · Aug 13, 2026
Grace Therapeutics Announces $10 Million Private PlacementGlobeNewsWire · Aug 4, 2026
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationGlobeNewsWire · Jul 28, 2026Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.13 | -$0.91 | Miss |
| Jun 18, 2026 | -$0.24 | -$0.07 | Beat |
| Feb 12, 2026 | -$0.09 | -$0.14 | Miss |
| Nov 13, 2025 | -$0.12 | -$0.08 | Beat |
| Aug 12, 2025 | -$0.22 | -$0.21 | Beat |
| Jun 23, 2025 | -$0.20 | $0.10 | Beat |